Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL

Video

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

There are 2 approved products now—–tisagenlecleucel (Kymriah), which is a 4-IBB product and axicabtagene-ciloleucel (Axi-cel; Yescarta), which is a CD28 product. They have very similar activity, says Andreadis. To date, clinical trials have shown response rates in the 50% range and long-term responses in 30% to 40% of patients, adds Andreadis.

However, they have different toxicity profiles. The toxicity with tisagenlecleucel is mainly low-grade cytokine release syndrome (CRS). There is a little bit of neurological toxicity, though it does not often require secondary agent support. Axi-cel has more of a robust and early onset toxicity profile, says Andreadis. Physicians have noted higher rates of CRS and neurotoxicity, as well as higher use of tocilizumab and steroids, which may make it more challenging to give in the outpatient setting.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.